Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL

Commentary
Video
Conference|ASH Annual Meeting and Exposition

Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

Paolo Ghia, MD, PhD, full professor, Medical Oncology, group leader, B-cell Neoplasia Unit, head, Strategic Research Program on CLL, Università Vita Salute San Raffaele, deputy director, Division of Experimental Oncology, San Raffaele Scientific Institute, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial (NCT03336333) investigating zanubrutinib (Brukinsa) vs bendamustine (Bendeka) plus rituximab (Rituxan; BR) in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without 17p deletions.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Related Content
Idalid Franco, MD, MPH, director of Equity Access and Inclusion in the Department of Radiation Oncology at Brigham and Women’s Hospital and an instructor at Harvard Medical School, both in Boston, Massachusetts

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer

April 20th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
R. Lor Randall, MD, FACS, of UC Davis Comprehensive Cancer Center

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority

April 19th 2024
Article
Talal Hilal, MD, MB, BCh

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

January 12th 2023
Podcast
Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

April 17th 2024
Article
Richard Maziarz, MD, medical director, Blood & Marrow Transplant & Cellular Therapy Program, Oregon Health and Science University

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

April 16th 2024
Article